Adding testosterone to HT may counteract harmful breast effects


Adding testosterone to combination hormone therapy with estrogen and progesterone may counteract breast cell proliferation in postmenopausal women, according to the results of a 6-month, prospective, randomized, double-blind, placebo-controlled trial.

In the study, 99 post-menopausal women received continuous combined estradiol 2 mg/norethisterone acetate 1 mg and either a testosterone patch releasing 300 µg/24 hours or a placebo patch.

The women in the placebo group had more than a fivefold increase in total breast cell proliferation from a median value of 1.1% at baseline to a median of 6.2% after 6 months (P<0.001). No such increase occurred in the testosterone group (1.6% vs. 2.0%). Proliferative changes were noted in both epithelial and stromal cells.

Until such time as more data are available, caution should be exercised in adding testosterone to traditional hormone therapy regimens.

Hofling M, Hirschberg AL, Skoog L, et al. Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. Menopause. 2007;14:183-190.

Burger HG. Should testosterone be added to estrogen-progestin therapy for breast protection? Menopause. 2007;14:159-162.

Recent Videos
The significance of the Supreme Court upholding mifepristone access | Image Credit:
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit:
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit:
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit:
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit:
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit:
raanan meyer, md
© 2024 MJH Life Sciences

All rights reserved.